Cefditoren and Ceftriaxone Enhance Complement-Mediated Immunity in the Presence of Specific Antibodies against Antibiotic-Resistant Pneumococcal Strains

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Ramos Sevillano, Elisa ^a   Rodríguez Sosa, Cinthya ^b   Cafini, Fabio ^c   Giménez, Maria Jose ^c   Navarro, Ana ^b   Sevillano, David ^c   Alou, Luis ^c   García, Ernesto ^a   Aguilar, Lorenzo ^c   Yuste, Jose ^a,b  

^a CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID P COMPONENT; C REACTIVE PROTEIN; CEFDITOREN; CEFTRIAXONE; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3B; SERUM AMYLOID P;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM ISOLATE; CELLULAR IMMUNITY; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMORAL IMMUNITY; MALE; MOUSE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN BINDING; STREPTOCOCCUS PNEUMONIAE;

ACUTE-PHASE PROTEINS; ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBODIES; BETA-LACTAMS; CEFTRIAXONE; CEPHALOSPORINS; COMPLEMENT ACTIVATION; COMPLEMENT C1Q; COMPLEMENT C3C; DRUG RESISTANCE, MICROBIAL; EGTAZIC ACID; FLOW CYTOMETRY; HUMANS; IMMUNE SYSTEM; MICE; PHAGOCYTOSIS; STREPTOCOCCUS PNEUMONIAE;

BACTERIA (MICROORGANISMS); STREPTOCOCCUS PNEUMONIAE;

EID: 84866025419     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0044135     Document Type: Article

References (38)

1. O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, et al. (2009) Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 374: 893-902.
2. Soriano F, Cafini F, Aguilar L, Tarragó D, Alou L, et al. (2008) Breakthrough in penicillin resistance? Streptococcus pneumoniae isolates with penicillin/cefotaxime MICs of 16 mg/L and their genotypic and geographical relatedness. J Antimicrob Chemother 62: 1234-1240.
3. Nuorti JP, Whitney CG, (2010) Prevention of pneumococcal disease among infants and children- use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 59: 1-18.
4. Walport MJ, (2001) Complement. Second of two parts. N Engl J Med 344: 1140-1144.
5. Walport MJ, (2001) Complement. First of two parts. N Engl J Med 344: 1058-1066.
6. Yuste J, Sen A, Truedsson L, Jönsson G, Tay LS, et al. (2008) Impaired opsonization with C3b and phagocytosis of Streptococcus pneumoniae in sera from subjects with defects in the classical complement pathway. Infect Immun 76: 3761-3770.
7. Brown JS, Hussell T, Gilliland SM, Holden DW, Paton JC, et al. (2002) The classical pathway is the dominant complement pathway required for innate immunity to Streptococcus pneumoniae infection in mice. Proc Natl Acad Sci U S A 99: 16969-16974.
8. Yuste J, Botto M, Bottoms SE, Brown JS, (2007) Serum amyloid P aids complement-mediated immunity to Streptococcus pneumoniae. PLoS Pathog 3: 1208-1219.
9. Mold C, Nakayama S, Holzer TJ, Gewurz H, Du Clos TW, (1981) C-reactive protein is protective against Streptococcus pneumoniae infection in mice. J Exp Med 154: 1703-1708.
10. Kang YS, Do Y, Lee HK, Park SH, Cheong C, et al. (2006) A dominant complement fixation pathway for pneumococcal polysaccharides initiated by SIGN-R1 interacting with C1q. Cell 125: 47-58.
11. Labro MT, (2000) Interference of antibacterial agents with phagocyte functions: immunomodulation or "immuno-fairy tales"? Clin Microbiol Rev 13: 615-650.
12. Milatovic D, (1983) Antibiotics and phagocytosis. Eur J Clin Microbiol 2: 414-425.
13. Yuste J, Giménez MJ, Jado I, Fenoll A, Aguilar L, et al. (2001) Enhanced decrease of blood colony counts by specific anti-pneumococcal antibodies in the presence of sub-inhibitory concentrations of amoxicillin. J Antimicrob Chemother 48: 594-595.
14. Casal J, Aguilar L, Jado I, Yuste J, Giménez MJ, et al. (2002) Effects of specific antibodies against Streptococcus pneumoniae on pharmacodynamic parameters of beta-lactams in a mouse sepsis model. Antimicrob Agents Chemother 46: 1340-1344.
15. Cafini F, Yuste J, Giménez MJ, Sevillano D, Aguilar L, et al. (2010) Enhanced in vivo activity of cefditoren in pre-immunized mice against penicillin-resistant S. pneumoniae (serotypes 6B, 19F and 23F) in a sepsis model. PLoS One 5: e12041.
16. Fenoll A, Martín Bourgon C, Muñoz R, Vicioso D, Casal J, (1991) Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolates causing systemic infections in Spain, 1979-1989. Rev Infect Dis 13: 56-60.
17. Ramos-Sevillano E, Moscoso M, García P, García E, Yuste J, (2011) Nasopharyngeal Colonization and Invasive Disease Are Enhanced by the Cell Wall Hydrolases LytB and LytC of Streptococcus pneumoniae. PLoS One 6: e23626.
18. Jongerius I, Kohl J, Pandey MK, Ruyken M, van Kessel KP, et al. (2007) Staphylococcal complement evasion by various convertase-blocking molecules. J Exp Med 204: 2461-2471.
19. Uria MJ, Zhang Q, Li Y, Chan A, Exley RM, et al. (2008) A generic mechanism in Neisseria meningitidis for enhanced resistance against bactericidal antibodies. J Exp Med 205: 1423-1434.
20. McCullers JA, Tuomanen EI, (2001) Molecular pathogenesis of pneumococcal pneumonia. Front Biosci 6: D877-889.
21. Bogaert D, van Belkum A, Sluijter M, Luijendijk A, de Groot R, et al. (2004) Colonisation by Streptococcus pneumoniae and Staphylococcus aureus in healthy children. Lancet 363: 1871-1872.
22. van der Poll T, Opal SM, (2009) Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet 374: 1543-1556.
23. Garcia-Bustos JF, Chait BT, Tomasz A, (1988) Altered peptidoglycan structure in a pneumococcal transformant resistant to penicillin. J Bacteriol 170: 2143-2147.
24. van Dam JE, Fleer A, Snippe H, (1990) Immunogenicity and immunochemistry of Streptococcus pneumoniae capsular polysaccharides. Antonie Van Leeuwenhoek 58: 1-47.
25. Jansen WT, Snippe H, (2004) Short-chain oligosaccharide protein conjugates as experimental pneumococcal vaccines. Indian J Med Res 119 Suppl: 7-12.
26. Jung E, Feldhoff RC, Walz BM, Drehs MM, Buchheit JQ, et al. (1998) Complement component C9 enhances the capacity of beta-lactam antibiotics to kill Escherichia coli in vitro and in vivo. Am J Med Sci 315: 307-313.
27. Darveau RP, Cunningham MD, (1990) Influence of subinhibitory concentrations of cephalosporins on the serum sensitivity of Pseudomonas aeruginosa. J Infect Dis 162: 914-921.
28. Subrt N, Mesak LR, Davies J, (2011) Modulation of virulence gene expression by cell wall active antibiotics in Staphylococcus aureus. J Antimicrob Chemother 66: 979-984.
29. Johnson HL, Chiou CC, Cho CT, (1999) Applications of acute phase reactants in infectious diseases. J Microbiol Immunol Infect 32: 73-82.
30. Almirall J, Bolibar I, Toran P, Pera G, Boquet X, et al. (2004) Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia. Chest 125: 1335-1342.
31. Du Clos TW, Mold C, (2001) The role of C-reactive protein in the resolution of bacterial infection. Curr Opin Infect Dis 14: 289-293.
32. Mold C, Gresham HD, Du Clos TW, (2001) Serum amyloid P component and C-reactive protein mediate phagocytosis through murine FcγRs. J Immunol 166: 1200-1205.
33. Thomas-Rudolph D, Du Clos TW, Snapper CM, Mold C, (2007) C-reactive protein enhances immunity to Streptococcus pneumoniae by targeting uptake to FcγR on dendritic cells. J Immunol 178: 7283-7291.
34. Gaziano R, Bozza S, Bellocchio S, Perruccio K, Montagnoli C, et al. (2004) Anti-Aspergillus fumigatus efficacy of pentraxin 3 alone and in combination with antifungals. Antimicrob Agents Chemother 48: 4414-4421.
35. Williams P, (1987) Sub-MICs of cefuroxime and ciprofloxacin influence interaction of complement and immunoglobulins with Klebsiella pneumoniae. Antimicrob Agents Chemother 31: 758-762.
36. Hyams C, Camberlein E, Cohen JM, Bax K, Brown JS, (2010) The Streptococcus pneumoniae capsule inhibits complement activity and neutrophil phagocytosis by multiple mechanisms. Infect Immun 78: 704-715.
37. Yuste J, Jado I, Giménez MJ, Aguilar L, Molero F, et al. (2002) Modification of bacteraemia by specific antibodies and relation with mortality in a pneumococcal mouse sepsis model. Clin Exp Immunol 128: 411-415.
38. Baxendale HE, Johnson M, Stephens RC, Yuste J, Klein N, et al. (2008) Natural human antibodies to pneumococcus have distinctive molecular characteristics and protect against pneumococcal disease. Clin Exp Immunol 151: 51-60.